Cancers, Vol. 11, Pages 1137: Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)

Cancers, Vol. 11, Pages 1137: Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) Cancers doi: 10.3390/cancers11081137 Authors: Maria Vittoria Dieci Lucia Del Mastro Michela Cinquini Filippo Montemurro Laura Biganzoli Laura Cortesi Alberto Zambelli Carmen Criscitiello Alessia Levaggi Benedetta Conte Massimo Calabrese Alba Fiorentino Caterina Marchiò Corrado Tinterri Veronica Andrea Fittipaldo Giovanni Pappagallo Stefania Gori In the absence of identified therapeutic targets, chemotherapy is the main systemic treatment option for triple-negative breast cancer (TNBC). The achievement of a pathological complete response (pCR) after neoadjuvant chemotherapy leads to good outcome, whereas patients not achieving a pCR are at high risk of relapse. Various trials have evaluated the inclusion of platinum in neoadjuvant chemotherapy regimens for TNBC, leading to non-univocal results. The panel of the Italian Association of Medical Oncology (AIOM) Guidelines on Breast Cancer developed a clinical recommendation on the addition of platinum to anthracycline/taxane-based neoadjuvant chemotherapy for TNBC by using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology and the Evidence to Decision framework...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research